| 316.24 -6.37 (-1.97%) | 07-10 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 381.5 | 1-year : | 445.59 |
| Resists | First : | 326.63 | Second : | 381.5 |
| Pivot price | 303.74  |
|||
| Supports | First : | 269.64 |
Second : | 234.41 |
| MAs | MA(5) : | 318.71 |
MA(20) : | 291.89 |
| MA(100) : | 230.61 |
MA(250) : | 199.1 |
|
| MACD | MACD : | 21 |
Signal : | 20.2 |
| %K %D | K(14,3) : | 89.3 |
D(3) : | 91.3 |
| RSI | RSI(14): 71 |
|||
| 52-week | High : | 326.63 | Low : | 120.68 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LGND ] has closed below upper band by 33.4%. Bollinger Bands are 99.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 15 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 323.21 - 324.79 | 324.79 - 326.33 |
| Low: | 306.1 - 308.05 | 308.05 - 309.96 |
| Close: | 312.59 - 315.72 | 315.72 - 318.79 |
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
Fri, 10 Jul 2026
Ligand Pharmaceuticals (LGND) Q1 2025 earnings summary - Quartr
Thu, 09 Jul 2026
Ligand Pharmaceuticals Incorporated Stock 12‑Month Price Target Raised to $299.22, Implies 5% Downside - TradingView
Thu, 09 Jul 2026
LGND Maintained by B of A Securities -- Price Target Raised to $388 - GuruFocus
Wed, 08 Jul 2026
Understanding the Setup: (LGND) and Scalable Risk - Stock Traders Daily
Wed, 08 Jul 2026
Ligand Pharmaceuticals (LGND) Investor Day 2024 Summary - Quartr
Mon, 06 Jul 2026
[Form 4] LIGAND PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 20 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 2.3 (%) |
| Held by Institutions | 106.3 (%) |
| Shares Short | 1,690 (K) |
| Shares Short P.Month | 1,510 (K) |
| EPS | 7.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 49.79 |
| Profit Margin | 55.9 % |
| Operating Margin | 33.5 % |
| Return on Assets (ttm) | 5.1 % |
| Return on Equity (ttm) | 17.1 % |
| Qtrly Rev. Growth | 14.1 % |
| Gross Profit (p.s.) | 11.39 |
| Sales Per Share | 13.69 |
| EBITDA (p.s.) | 6.7 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 124 (M) |
| Levered Free Cash Flow | 142 (M) |
| PE Ratio | 41.17 |
| PEG Ratio | 1.5 |
| Price to Book value | 6.35 |
| Price to Sales | 23.08 |
| Price to Cash Flow | 51.31 |
| Dividend | 9.35 |
| Forward Dividend | 0 |
| Dividend Yield | 2.9% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|